ArticleJournal of inflammation (London, England)2025
Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition.
Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases.Signal transduction and targeted therapy · 2026Review
- Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.Journal for immunotherapy of cancer · 2026Article
- Tumor-associated neutrophils in pancreatic ductal adenocarcinoma: mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Imaging Reactive Oxygen Species with L-012 Reveals Neutrophil Extracellular Trap Formation in Pancreatic Ductal Adenocarcinoma.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMetastatic pancreatic adenocarcinoma has a 5-year survival of only 3%. Neutrophil extracellular traps are formed when neutrophils expel their intracellular contents and have been intricately linked to metastases. Hydroxychloroquine is an FDA-approved anti-malarial drug and neutrophil extracellular trap inhibitor with high potential for clinical translation. This study investigates the impact of hydroxychloroquine treatment on pancreatic metastases.
resultsHydroxychloroquine reduced metastatic tumor burden via a neutrophil extracellular trap independent mechanism and resulted in prolonged survival. Hydroxychloroquine inhibited the function of myeloperoxidase in vitro via direct binding with a Kd of 9.74 mM. Myeloperoxidase inhibition via hydroxychloroquine in vivo was the direct result of suppressed activity. Hydroxychloroquine mediated myeloperoxidase inhibition was also demonstrated in metastatic pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy.
conclusionHydroxychloroquine suppressed pancreatic metastases growth through myeloperoxidase inhibition, leading to a significant increase in survival. Corroborative data supports this mechanism in metastatic pancreatic adenocarcinoma patients treated with hydroxychloroquine. These data provide important insight into the role of myeloperoxidase in pancreatic metastases and the potential use of hydroxychloroquine in metastatic pancreatic adenocarcinoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.